国际中医中药杂志
國際中醫中藥雜誌
국제중의중약잡지
INTERNATIONAL JOURNAL OF TRIDITIONAL CHINESE MEDICINE
2009年
2期
136-137
,共2页
临床期糖尿病肾病%肾功能%血脂%糖肾通宝饮%贝那普利
臨床期糖尿病腎病%腎功能%血脂%糖腎通寶飲%貝那普利
림상기당뇨병신병%신공능%혈지%당신통보음%패나보리
Diabetic nephropathy in clinical stage%Kidney function%Blood lipid%Tangshentongbao decoction%Benazepril
目的 观察中药糖肾通宝饮联合贝那普利治疗临床期糖尿病肾病(diabetic nephropathy,DN)患者肾功能的临床疗效.方法 采用随机、对照方法,将62例临床期DN患者分为两组各31例.两组均给了相同饮食、降糖和对症处理,治疗组应用中药糖肾通宝饮联合贝那普利治疗,对照组应用胰激肽原酶肠溶片合贝那普利治疗,疗程均为8周,观察2组患者治疗前后症状体征变化,测定24h尿蛋白总量(24-hour urinay protein,24h Upro)、血肌酐(serumcreatimine,SCr),肌酐清除率(serum creatinine clearance erate,CCr)尿素氮(blood urea nitrogen,BUN)、三酰甘油(triglyceride,TG)、总胆崮醇(cholesterd,CHO)、低密度脂蛋白胆固醇(low density lipoprotein-cholesterol,LDL-C)的变化.结果 治疗组治疗后24hUpro、SCr、TG、CHO、LDL-C均降低(P<0.01或P<0.05),优于对照组.结论 中药糖肾通宝饮联合贝那普利方案治疗临床期DN可明显降低24hUpro,SCr,降脂作用优于单纯西药.
目的 觀察中藥糖腎通寶飲聯閤貝那普利治療臨床期糖尿病腎病(diabetic nephropathy,DN)患者腎功能的臨床療效.方法 採用隨機、對照方法,將62例臨床期DN患者分為兩組各31例.兩組均給瞭相同飲食、降糖和對癥處理,治療組應用中藥糖腎通寶飲聯閤貝那普利治療,對照組應用胰激肽原酶腸溶片閤貝那普利治療,療程均為8週,觀察2組患者治療前後癥狀體徵變化,測定24h尿蛋白總量(24-hour urinay protein,24h Upro)、血肌酐(serumcreatimine,SCr),肌酐清除率(serum creatinine clearance erate,CCr)尿素氮(blood urea nitrogen,BUN)、三酰甘油(triglyceride,TG)、總膽崮醇(cholesterd,CHO)、低密度脂蛋白膽固醇(low density lipoprotein-cholesterol,LDL-C)的變化.結果 治療組治療後24hUpro、SCr、TG、CHO、LDL-C均降低(P<0.01或P<0.05),優于對照組.結論 中藥糖腎通寶飲聯閤貝那普利方案治療臨床期DN可明顯降低24hUpro,SCr,降脂作用優于單純西藥.
목적 관찰중약당신통보음연합패나보리치료림상기당뇨병신병(diabetic nephropathy,DN)환자신공능적림상료효.방법 채용수궤、대조방법,장62례림상기DN환자분위량조각31례.량조균급료상동음식、강당화대증처리,치료조응용중약당신통보음연합패나보리치료,대조조응용이격태원매장용편합패나보리치료,료정균위8주,관찰2조환자치료전후증상체정변화,측정24h뇨단백총량(24-hour urinay protein,24h Upro)、혈기항(serumcreatimine,SCr),기항청제솔(serum creatinine clearance erate,CCr)뇨소담(blood urea nitrogen,BUN)、삼선감유(triglyceride,TG)、총담고순(cholesterd,CHO)、저밀도지단백담고순(low density lipoprotein-cholesterol,LDL-C)적변화.결과 치료조치료후24hUpro、SCr、TG、CHO、LDL-C균강저(P<0.01혹P<0.05),우우대조조.결론 중약당신통보음연합패나보리방안치료림상기DN가명현강저24hUpro,SCr,강지작용우우단순서약.
Objective To assess the protective effect of Tangshentongbao decoction combined benazepril on renal function of the patients with diabetic nephropathy(DN) in clinical stage and to make a effective contrast to the therapy with western medicine. Methods 62 patients with DN in clinical stage were randomly divided into a control group and a treatment group, with 31 patients in each group. Both groups were supplied with the same food, adopted glucose control therapy and symptoms orientated treatment. On these basis, the treatment group was administered with Tangshentongbao decoction combined benazepril, and the control group was taken kallikrein enteric tablet combined benazepril. The therapeutic courses for both groups were 8 months. The changes of symptoms and physical signs, 24-hour urinay protein (24hUpro), serum cteatimine (SCr), serum creatinine clearance erate (CCr) , blood urea nitrogen (BUN), triglyceride (TG), cholesterd (CHO) and low density lipoprotein-cholesterol (LDL-C)of the two groups were separately assessed. Results 24hUpro, SCr, TG, CHO and LDL-C of treated group were all reduced after the treatment (P<0.01 or P <0.05), showing significant difference compared with the control group. Conclusion 24hUpro and SCr of patients with DN in clinical stage can be evidently reduced by Tangshentongbao decoction, and the effect of reducing blood lipid is remarkable better than western medicine alone.
